BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 115912
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.115912
Analysis of histopathological and clinical prognostic factors in lymphomas involving the gastrointestinal system
Dilara Ozyigit Buyuktalanci, Ebru Cakir, Betül Bolat Kucukzeybek, Sultan Deniz Altindag, Asu Fergun Yilmaz, Hatice Demet Kiper, Osman Nuri Dilek
Dilara Ozyigit Buyuktalanci, Department of Pathology, Basaksehir Cam and Sakura City Hospital, Istanbul 34490, Türkiye
Ebru Cakir, Betül Bolat Kucukzeybek, Department of Pathology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir 35730, Türkiye
Sultan Deniz Altindag, Department of Pathology, Bandırma Onyedi Eylul University, Balikesir 10200, Türkiye
Asu Fergun Yilmaz, Hatice Demet Kiper, Department of Hematology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir 35730, Türkiye
Osman Nuri Dilek, Department of General Surgery, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir 35730, Türkiye
Author contributions: Buyuktalanci DO and Cakir E participated in the conception and design of the study and were involved in the acquisition, analysis, or interpretation of data; Buyuktalanci DO, Cakir E, and Kucukzeybek BB wrote the manuscript; all authors critically reviewed and provided final approval of the manuscript; all were responsible for the decision to submit it for publication.
Institutional review board statement: This investigation was approved by the Institutional Ethics Committee of Izmir Katip Celebi University Ataturk Training and Research Hospital, No. 2025-SAEK-0951.
Informed consent statement: Patient consent was waived due to the study's retrospective nature.
Conflict-of-interest statement: All authors declare that there are no conflicts of interest in connection with this paper, and the material described is not under publication or consideration for publication elsewhere.
Data sharing statement: The data underlying this study are available in the published articles.
Corresponding author: Dilara Ozyigit Buyuktalanci, MD, Chief, Department of Pathology, Basaksehir Cam and Sakura City Hospital, Başakşehir, İstanbul 34490, Türkiye. dr.dilaraozyigit@gmail.com
Received: October 29, 2025
Revised: November 20, 2025
Accepted: December 23, 2025
Published online: March 15, 2026
Processing time: 134 Days and 20.1 Hours
Abstract
BACKGROUND

Primary gastrointestinal lymphomas (PGIL) are rare tumors that can involve the whole gastrointestinal (GI) tract. Although lymphomas can originate from any part of the gastrointestinal tract, the most common sites are the stomach, small intestine, and ileocecal region.

AIM

To examine the clinicopathologic and prognostic features of PGIL.

METHODS

We performed a retrospective single-center analysis of 111 patients diagnosed with gastrointestinal lymphomas (GIL) at Izmir Katip Celebi University Ataturk Training and Research Hospital. Histopathological, clinical, and prognostic parameters, including pathological subtype, Helicobacter pylori infection, tumor stage, grade, Performance Score (PS), International Prognostic Index, lactate dehydrogenase (LDH) level, and treatment modality of PGILs (2006-2018), were retrospectively analyzed using SPSS 25.0.

RESULTS

The study included 111 patients diagnosed with GIL. The median age was 66 years (60 males, 51 females). Sites of involvement were stomach (67.5%), small bowel (18%), large bowel/rectum (12.6%), and pancreas (1.8%). Among 62 patients with primary GIL, 49 (79%) had diffuse large B-cell lymphoma (DLBCL), 6 (9.7%) had extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, 2 (3.2%) had mantle cell lymphoma, 2 (3.2%) had unclassified B-cell lymphoma, and 2 (3.2%) had T-cell lymphoma. The 1-, 3-, and 5-year overall survival (OS) and event-free survival rates were 67%, 56%, 47%, and 80%, 58.6%, 54.4%, respectively. In univariate analysis, LDH level (LDH ≥ 270 U/L) (P = 0.029), PS [Eastern Cooperative Oncology Group (ECOG) ≥ 2] (P < 0.0001), and surgical treatment (P = 0.002) were associated with survival. In multivariate analysis, a poor PS (ECOG ≥ 2) (P = 0.010) was an independent predictor of poor OS.

CONCLUSION

In this study, the stomach was the most frequently involved site, DLBCL was the predominant subtype, and poor performance status was associated with poorer survival.

Keywords: Gastrointestinal system; Lymphoma; Gastric lymphoma; Intestinal lymphoma

Core Tip: Primary gastrointestinal lymphoma (PGIL) is a rare and heterogeneous disease with diverse clinicopathologic and prognostic features. In this retrospective study of 62 primary cases, the stomach was the most frequently involved site, and diffuse large B-cell lymphoma was the predominant subtype. Poor performance status emerged as an independent predictor of reduced overall survival. This finding contributes to a better understanding of prognostic determinants in PGIL and may guide individualized management strategies in clinical practice.